ICCVAM’s LLNA report available
This article was originally published in The Rose Sheet
Executive Summary
11Report from scientific panel convened in late April by the International Coordinating Committee on the Validation of Alternative Methods to review murine local lymph node assay test is now available at the NICEATM/ICCVAM Web site; public comment is invited. LLNA test is used to determine if substances may cause allergic contact dermatitis. Panel greenlighted two nonradioactive versions of the LLNA, with certain limitations, and showed support for third method "contingent upon demonstration of adequate interlaboratory reproducibility ... and an audit to verify summary data submitted for review" (2"The Rose Sheet" May 18, 2009, In Brief). ICCVAM will consider report and public feedback before making recommendation to federal agencies, which could lead to further reduction of animal use in product safety testing. ICCVAM panel met May 19-21 to consider alternative methods for gauging the eye irritation potential of antimicrobial cleaning products and determined data insufficient to support the EpiOcular, Cytosensor Microphysiometer and bovine corneal opacity and permeability assays (3"The Rose Sheet" June 1, 2009, In Brief)
You may also be interested in...
ICCVAM convenes international panel
Interagency Coordinating Committee on the Validation of Alternative Methods placed three nonradioactive modified versions and new applications for the murine local lymph node assay (LLNA) before an independent scientific peer review panel April 28-29 in Bethesda, Md. Panel was made up of 15 experts from six countries, consistent with spirit of a memorandum of cooperation between U.S., EU, Canada and Japan, signed immediately beforehand, aimed at speeding the global adoption of non-animal testing methods through each country's increased involvement in the process by which tests are evaluated and recommended to regulators (1"The Rose Sheet" May 4, 2009, p. 6). Panelists concluded that available data supports use of the LLNA:DA and LLNA:BrdU-ELISA to identify substances as potential skin sensitizers, with certain limitations, while deferring a formal recommendation for a third version of the LLNA (LLNA:BrdU-FC) until an independent audit of supporting data has been conducted. Panel's full report from the meeting will be published in early June; in the meantime, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods offers a detailed summary online
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.